Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PROPEL-36: bempegaldesleukin plus pembrolizumab versus pembrolizumab in first-line PD-L1-positive recurrent or metastatic head and neck squamous cell carcinoma
2021-002461-18Phase 2Terminated
- Sponsor
- Nektar Therapeutics
- Start
- Sep 2021
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in head and neck squamous cell carcinoma (HNSCC) comparing Bempeg + Keytruda with Keytruda monotherapy (2 arms). Primary endpoints: Overall survival and Progression-free survival. Started Sep 2021; status: terminated.
02
Drugs
bempegaldesleukinpembrolizumab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on 2021-002461-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-002461-18.